475 Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade
Namrata S. Patil(Gene Therapy Laboratory), David S. Shames(Gene Therapy Laboratory), John Silva, Barzin Y. Nabet(Gene Therapy Laboratory), Shyam Srivats, Chikara Takahashi, Eugene Chiang, Joy Han, Pallavi Daggumati, Lisa McGinnis(Stanford Medicine), Alexis Dunkle(Duke University Hospital), Nandini Molden, Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Wendy Connolly, Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Byoung Chul Cho(Yonsei University), Bill O’Gorman, Ignacio Gil‐Bazo(Navarre Institute of Health Research), Melissa Johnson, Ira Mellman(Unknown), Xiangnan Guan(Unknown), Enriqueta Felip(Institut Català d'Ornitologia), Ruozhen Hu, Robert E. Johnston(University of North Carolina at Chapel Hill), Patrick Chang, Thinh Pham, Raymond D. Meng, Yoonha Choi(Ewha Womans University), Carlos Bais(Eos Neuroscience (United States)), Amelia Yuen Shan Au‐Yeung, Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center)
Cited by 3
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k